Editas Medicine, Inc. (EDIT)
After hours:
| Previous close | 5.67 |
| Open | 5.73 |
| Bid | 5.64 x 100 |
| Ask | 5.68 x 1100 |
| Day's range | 5.55 - 5.78 |
| 52-week range | 5.11 - 11.91 |
| Volume | |
| Avg. volume | 1,962,520 |
| Market cap | 465.448M |
| Beta (5Y monthly) | 2.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.02 |
| Earnings date | 03 June 2024 - 18 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.64 |
Simply Wall St.Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
Key Insights Significantly high institutional ownership implies Editas Medicine's stock price is sensitive to their...
GlobeNewswireEditas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.Particip
- GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
